Brokerages Set Lantheus Holdings, Inc. (NASDAQ:LNTH) PT at $104.14

Lantheus Holdings, Inc. (NASDAQ:LNTH) has received an average rating of “Moderate Buy” from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $104.14.

Several equities research analysts have recently weighed in on the company. B. Riley reduced their price objective on Lantheus from $113.00 to $95.00 and set a “buy” rating for the company in a research note on Wednesday, January 10th. JMP Securities reissued a “market outperform” rating and set a $100.00 price objective on shares of Lantheus in a research note on Friday, February 23rd. Truist Financial reissued a “buy” rating and set a $82.00 price objective (up from $80.00) on shares of Lantheus in a research note on Monday, February 26th. Finally, StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th.

Insider Transactions at Lantheus

In other Lantheus news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the company’s stock in a transaction dated Wednesday, March 6th. The shares were acquired at an average cost of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the purchase, the insider now owns 116,773,394 shares of the company’s stock, valued at approximately $110,934,724.30. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Mary Anne Heino sold 93,863 shares of the business’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the transaction, the director now directly owns 251,643 shares in the company, valued at $16,434,804.33. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were purchased at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the purchase, the insider now directly owns 116,773,394 shares of the company’s stock, valued at $110,934,724.30. The disclosure for this purchase can be found here. 2.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Lantheus

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Macquarie Group Ltd. grew its stake in shares of Lantheus by 21.7% in the 1st quarter. Macquarie Group Ltd. now owns 605 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 108 shares during the period. Parkside Financial Bank & Trust grew its stake in shares of Lantheus by 36.6% in the 3rd quarter. Parkside Financial Bank & Trust now owns 582 shares of the medical equipment provider’s stock valued at $40,000 after purchasing an additional 156 shares during the period. RFG Advisory LLC grew its stake in shares of Lantheus by 4.4% in the 3rd quarter. RFG Advisory LLC now owns 3,940 shares of the medical equipment provider’s stock valued at $274,000 after purchasing an additional 167 shares during the period. Prosperity Financial Group Inc. grew its stake in shares of Lantheus by 6.2% in the 3rd quarter. Prosperity Financial Group Inc. now owns 2,967 shares of the medical equipment provider’s stock valued at $206,000 after purchasing an additional 173 shares during the period. Finally, Vanguard Personalized Indexing Management LLC grew its stake in shares of Lantheus by 3.1% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 6,217 shares of the medical equipment provider’s stock valued at $432,000 after purchasing an additional 188 shares during the period. 99.06% of the stock is currently owned by institutional investors.

Lantheus Stock Up 2.5 %

Shares of Lantheus stock opened at $61.73 on Friday. The company has a current ratio of 5.80, a quick ratio of 5.45 and a debt-to-equity ratio of 0.69. The business’s 50 day simple moving average is $60.39 and its 200-day simple moving average is $63.01. The stock has a market capitalization of $4.23 billion, a price-to-earnings ratio of 13.30 and a beta of 0.54. Lantheus has a twelve month low of $50.20 and a twelve month high of $100.85.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, beating the consensus estimate of $1.33 by $0.26. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. The firm had revenue of $354.00 million for the quarter, compared to analysts’ expectations of $350.44 million. Equities research analysts forecast that Lantheus will post 5.72 earnings per share for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.